103.21 0.00 (0.00%)
After hours: 4:49PM EST
|Bid||103.51 x 900|
|Ask||103.44 x 800|
|Day's Range||101.95 - 103.61|
|52 Week Range||94.59 - 141.86|
|Beta (5Y Monthly)||1.75|
|PE Ratio (TTM)||9.65|
|Earnings Date||Apr 22, 2020 - Apr 26, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||142.63|
While women make up one-quarter of leadership teams among the 25 largest publicly traded companies in Massachusetts, they represent just 4 percent of CEOs, according to a new report.
Alexion Pharmaceuticals (ALXN) is a biopharmaceutical company that researches and manufactures treatments of severe and rare health disorders; I consider this an undervalued growth stock, notes Crista Huff, editor of Cabot Undervalued Stocks Advisor.
Last week, you might have seen that Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) released its full-year result to the...
Vertex (VRTX) rides high on earnings and revenue beat in Q4. The company provides solid outlook for 2020 resulting in the shares to go up in after-hours trading.
Frustrated with the slow pace of drug discovery and desperate to help their loved ones, untrained family members take the work into their own hands by starting biopharma companies. But few such companies have been successful.
Alexion Pharmaceuticals topped Wall Street's fourth-quarter revenue and adjusted earnings expectations early Thursday, but Alexion Pharma stock slipped on mixed guidance for 2020.
View more earnings on ALXN See more from Benzinga Recap: Alliance Data Systems Q4 Earnings AmerisourceBergen: Q1 Earnings Insights 17 Healthcare Stocks Moving In Thursday's Pre-Market Session © 2020 Benzinga.com. ...
Alexion (ALXN) delivered earnings and revenue surprises of 3.44% and 1.72%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
The purchase price could grow if the Food and Drug Administration approves an experimental therapy that combines a product from each company.
Acceleron (XLRN) stock surges as sotatercept meets primary and secondary endpoints in a phase II study in patients with pulmonary arterial hypertension.
Investors seeking out high growth for their portfolios will often turn to biotech stocks. The biotechnology industry, which has become densely populated as our understanding of living systems and organisms continues to expand, has earned a reputation on Wall Street for its explosive potential ... and high volatility.In contrast to companies in other sectors, the gains and losses in even the best biotech stocks hinge less on earnings results, and more on a few key indicators such as trial-data readouts or verdicts from regulatory agencies. Product approvals unlock vital revenues, so a single positive update can function as a catalyst that propels shares to new highs.Of course, there's a reason risk-averse investors shy away from these stocks: The opposite also holds true.Wall Street pros rightly advise a cautious approach when evaluating the biotechnology industries. We find that monitoring the analyst community can be helpful on a couple fronts: For one, we can see where the pros are putting their faith. Also, analysts can provide much-needed insight into many stocks that get little media coverage, and whose progress can be difficult to gauge unless you're a medical expert.We used TipRanks' Stock Screener tool to comb through hundreds of biotechnology stocks to identify promising picks - ones that have received enough lopsided support from analysts that they earn TipRanks' top Strong Buy consensus rating. Here, we have found five top biotech stocks with overwhelmingly bullish sentiment from the analyst community, and price-growth projections of between 28% and 82%. SEE ALSO: 8 Stock Picks Getting Hit by Coronavirus Fears
On Vertex's (VRTX) fourth-quarter earnings call, investor focus will be on the sales uptake of its CF drugs and the unveiling plans for the newly-approved Trikafta triple combination regimen.
The Zacks Analyst Blog Highlights: Lear, SEI Investments, Alexion Pharmaceuticals and Apartment Investment and Management